HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_97
Abstract: Introduction: Ibrutinib (ibr), a first‐in‐class, once‐daily inhibitor of Bruton's tyrosine kinase, is approved in the EU for the treatment of CLL. Ibr results in rapid reduction in lymphadenopathy, often accompanied by early, transient lymphocytosis. Venetoclax… read more here.
Keywords: risk; high risk; resonate; ibr ... See more keywords
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03830-8
Abstract: After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data… read more here.
Keywords: real world; world; lymphocytic leukemia; resonate ... See more keywords
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006434
Abstract: Key Points Long-term RESONATE-2 data show sustained PFS and OS benefits (medians not reached) for first-line ibrutinib treatment in patients with CLL. Forty-two percent of patients continued ibrutinib for up to 8 years; dose management… read more here.
Keywords: ibrutinib; treatment patients; first line; line ibrutinib ... See more keywords